Loading…

Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes

Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain,...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1998-09, Vol.92 (5), p.1565-1575
Main Authors: WHITWAM, T, HASKINS, M. E, HENTHORN, P. S, KRASZEWSKI, J. N, KLEIMAN, S. E, SEIDEL, N. E, BODINE, D. M, PUCK, J. M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713
cites cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713
container_end_page 1575
container_issue 5
container_start_page 1565
container_title Blood
container_volume 92
creator WHITWAM, T
HASKINS, M. E
HENTHORN, P. S
KRASZEWSKI, J. N
KLEIMAN, S. E
SEIDEL, N. E
BODINE, D. M
PUCK, J. M
description Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.
doi_str_mv 10.1182/blood.v92.5.1565
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73867453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73867453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</originalsourceid><addsrcrecordid>eNo9kV2L1DAUhoMo67h6742QC_HKjvlo0tQ7WfyCgYVFvQ1pejqNJk1N2lnnf_iDzbizCyGBc573PeS8CL2kZEupYu86H2O_PbRsK7ZUSPEIbahgqiKEkcdoQwiRVd029Cl6lvNPQmjNmbhAF6Ukhao36O8NLCkeXDIeB5N-uWmP44CtmdwEuIvlKuUUb_F7vIvTvloghbd4dPux8nAAj-HPnCBnF6eTcFyDmbCbCuZhLXYVwwkszEtM2MYQCrY3IRhsR-NO5P0sfwzzGO1xgfwcPRmMz_Di_F6i758-frv6Uu2uP3-9-rCrLONqqXpLDfTSMENFN4DkSgkLgySmEXXHO-Cst6IdBhDQc8VtbantW1YOU9BQfone3PnOKf5eIS86uGzBezNBXLNuuJJNLXgByR1oU8w5waDn5MpejpoSfQpC_w9C_2iZFvoURJG8OnuvXYD-QXDefOm_PvdNtsYPyUzW5QeMcSnLJ_k__SaWAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73867453</pqid></control><display><type>article</type><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><source>ScienceDirect</source><creator>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</creator><creatorcontrib>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</creatorcontrib><description>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.v92.5.1565</identifier><identifier>PMID: 9716584</identifier><language>eng</language><publisher>Washington, DC: The Americain Society of Hematology</publisher><subject>AIDS/HIV ; Animals ; Biological and medical sciences ; Biotechnology ; Bone Marrow - metabolism ; Bone Marrow Transplantation ; Dogs ; Fundamental and applied biological sciences. Psychology ; Gene Expression ; Gene therapy ; Gene Transfer Techniques ; Genetic Markers ; Genetic Therapy ; Granulocyte Colony-Stimulating Factor - pharmacology ; Health. Pharmaceutical industry ; Humans ; Immunosuppression ; Industrial applications and implications. Economical aspects ; Lymphocytes - metabolism ; Receptors, Interleukin-2 - genetics ; Retroviridae - genetics ; Severe Combined Immunodeficiency - genetics ; Severe Combined Immunodeficiency - therapy ; Stem Cell Factor - pharmacology ; X Chromosome</subject><ispartof>Blood, 1998-09, Vol.92 (5), p.1565-1575</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</citedby><cites>FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2366238$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9716584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WHITWAM, T</creatorcontrib><creatorcontrib>HASKINS, M. E</creatorcontrib><creatorcontrib>HENTHORN, P. S</creatorcontrib><creatorcontrib>KRASZEWSKI, J. N</creatorcontrib><creatorcontrib>KLEIMAN, S. E</creatorcontrib><creatorcontrib>SEIDEL, N. E</creatorcontrib><creatorcontrib>BODINE, D. M</creatorcontrib><creatorcontrib>PUCK, J. M</creatorcontrib><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><title>Blood</title><addtitle>Blood</addtitle><description>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</description><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biotechnology</subject><subject>Bone Marrow - metabolism</subject><subject>Bone Marrow Transplantation</subject><subject>Dogs</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression</subject><subject>Gene therapy</subject><subject>Gene Transfer Techniques</subject><subject>Genetic Markers</subject><subject>Genetic Therapy</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Health. Pharmaceutical industry</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Industrial applications and implications. Economical aspects</subject><subject>Lymphocytes - metabolism</subject><subject>Receptors, Interleukin-2 - genetics</subject><subject>Retroviridae - genetics</subject><subject>Severe Combined Immunodeficiency - genetics</subject><subject>Severe Combined Immunodeficiency - therapy</subject><subject>Stem Cell Factor - pharmacology</subject><subject>X Chromosome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNo9kV2L1DAUhoMo67h6742QC_HKjvlo0tQ7WfyCgYVFvQ1pejqNJk1N2lnnf_iDzbizCyGBc573PeS8CL2kZEupYu86H2O_PbRsK7ZUSPEIbahgqiKEkcdoQwiRVd029Cl6lvNPQmjNmbhAF6Ukhao36O8NLCkeXDIeB5N-uWmP44CtmdwEuIvlKuUUb_F7vIvTvloghbd4dPux8nAAj-HPnCBnF6eTcFyDmbCbCuZhLXYVwwkszEtM2MYQCrY3IRhsR-NO5P0sfwzzGO1xgfwcPRmMz_Di_F6i758-frv6Uu2uP3-9-rCrLONqqXpLDfTSMENFN4DkSgkLgySmEXXHO-Cst6IdBhDQc8VtbantW1YOU9BQfone3PnOKf5eIS86uGzBezNBXLNuuJJNLXgByR1oU8w5waDn5MpejpoSfQpC_w9C_2iZFvoURJG8OnuvXYD-QXDefOm_PvdNtsYPyUzW5QeMcSnLJ_k__SaWAQ</recordid><startdate>19980901</startdate><enddate>19980901</enddate><creator>WHITWAM, T</creator><creator>HASKINS, M. E</creator><creator>HENTHORN, P. S</creator><creator>KRASZEWSKI, J. N</creator><creator>KLEIMAN, S. E</creator><creator>SEIDEL, N. E</creator><creator>BODINE, D. M</creator><creator>PUCK, J. M</creator><general>The Americain Society of Hematology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980901</creationdate><title>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</title><author>WHITWAM, T ; HASKINS, M. E ; HENTHORN, P. S ; KRASZEWSKI, J. N ; KLEIMAN, S. E ; SEIDEL, N. E ; BODINE, D. M ; PUCK, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biotechnology</topic><topic>Bone Marrow - metabolism</topic><topic>Bone Marrow Transplantation</topic><topic>Dogs</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression</topic><topic>Gene therapy</topic><topic>Gene Transfer Techniques</topic><topic>Genetic Markers</topic><topic>Genetic Therapy</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Health. Pharmaceutical industry</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Industrial applications and implications. Economical aspects</topic><topic>Lymphocytes - metabolism</topic><topic>Receptors, Interleukin-2 - genetics</topic><topic>Retroviridae - genetics</topic><topic>Severe Combined Immunodeficiency - genetics</topic><topic>Severe Combined Immunodeficiency - therapy</topic><topic>Stem Cell Factor - pharmacology</topic><topic>X Chromosome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WHITWAM, T</creatorcontrib><creatorcontrib>HASKINS, M. E</creatorcontrib><creatorcontrib>HENTHORN, P. S</creatorcontrib><creatorcontrib>KRASZEWSKI, J. N</creatorcontrib><creatorcontrib>KLEIMAN, S. E</creatorcontrib><creatorcontrib>SEIDEL, N. E</creatorcontrib><creatorcontrib>BODINE, D. M</creatorcontrib><creatorcontrib>PUCK, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WHITWAM, T</au><au>HASKINS, M. E</au><au>HENTHORN, P. S</au><au>KRASZEWSKI, J. N</au><au>KLEIMAN, S. E</au><au>SEIDEL, N. E</au><au>BODINE, D. M</au><au>PUCK, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1998-09-01</date><risdate>1998</risdate><volume>92</volume><issue>5</issue><spage>1565</spage><epage>1575</epage><pages>1565-1575</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Optimization of retroviral gene transfer into hematopoietic cells of the dog will facilitate gene therapy of canine X-linked severe combined immunodeficiency (XSCID) and in turn advance similar efforts to treat human XSCID. Both canine and human XSCID are caused by defects in the common gamma chain, gammac, of receptors for interleukin-2 and other cytokines. In this study, normal dogs were given retrovirally transduced bone marrow cells with and without preharvest mobilization by the canine growth factors granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF). Harvey sarcoma virus and Moloney murine leukemia virus constructs were used, both containing cDNA encoding human gammac. The Harvey-based vector transduced into cytokine-primed marrow yielded persistent detectable provirus in bone marrow and blood and expression of human gammac on peripheral lymphocytes. In three dogs, human gammac expression disappeared after 19 to 34 weeks but reappeared and was sustained, in one dog beyond 16 months posttransplantation, upon immunosuppression with cyclosporin A and prednisone, with up to 25% of lymphocytes expressing human gammac. The long-term expression of human gammac in a high proportion of normal canine lymphocytes predicts that retrovirus-mediated gene correction of hematopoietic cells may prove to be of clinical benefit in humans affected with this XSCID. This is a US government work. There are no restrictions on its use.</abstract><cop>Washington, DC</cop><pub>The Americain Society of Hematology</pub><pmid>9716584</pmid><doi>10.1182/blood.v92.5.1565</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 1998-09, Vol.92 (5), p.1565-1575
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_73867453
source ScienceDirect
subjects AIDS/HIV
Animals
Biological and medical sciences
Biotechnology
Bone Marrow - metabolism
Bone Marrow Transplantation
Dogs
Fundamental and applied biological sciences. Psychology
Gene Expression
Gene therapy
Gene Transfer Techniques
Genetic Markers
Genetic Therapy
Granulocyte Colony-Stimulating Factor - pharmacology
Health. Pharmaceutical industry
Humans
Immunosuppression
Industrial applications and implications. Economical aspects
Lymphocytes - metabolism
Receptors, Interleukin-2 - genetics
Retroviridae - genetics
Severe Combined Immunodeficiency - genetics
Severe Combined Immunodeficiency - therapy
Stem Cell Factor - pharmacology
X Chromosome
title Retroviral marking of canine bone marrow : Long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A15%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retroviral%20marking%20of%20canine%20bone%20marrow%20:%20Long-term,%20high-level%20expression%20of%20human%20interleukin-2%20receptor%20common%20gamma%20chain%20in%20canine%20lymphocytes&rft.jtitle=Blood&rft.au=WHITWAM,%20T&rft.date=1998-09-01&rft.volume=92&rft.issue=5&rft.spage=1565&rft.epage=1575&rft.pages=1565-1575&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.v92.5.1565&rft_dat=%3Cproquest_cross%3E73867453%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c238t-dc1aed6a2a15bfe63885cef60a754b3be32dc59ffe5ed383c4c1cd92d9228e713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73867453&rft_id=info:pmid/9716584&rfr_iscdi=true